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a b s t r a c t
Virus-encoded tumor suppressor p53 transgene expression has been successfully used in vesicular
stomatitis virus (VSV) and other oncolytic viruses (OVs) to enhance their anticancer activities. However,
p53 is also known to inhibit virus replication via enhanced type I interferon (IFN) antiviral responses. To
examine whether p53 transgenes enhance antiviral signaling in human pancreatic ductal adenocarci-
noma (PDAC) cells, we engineered novel VSV recombinants encoding human p53 or the previously
described chimeric p53-CC, which contains the coiled-coil (CC) domain from breakpoint cluster region
(BCR) protein and evades the dominant-negative activities of endogenously expressed mutant p53.
Contrary to an expected enhancement of antiviral signaling by p53, our global analysis of gene
expression in PDAC cells showed that both p53 and p53-CC dramatically inhibited type I IFN responses.
Our data suggest that this occurs through p53-mediated inhibition of the NF-κB pathway. Importantly,
VSV-encoded p53 or p53-CC did not inhibit antiviral signaling in non-malignant human pancreatic
ductal cells, which retained their resistance to all tested VSV recombinants. To the best of our knowledge,
this is the ﬁrst report of p53-mediated inhibition of antiviral signaling, and it suggests that OV-encoded
p53 can simultaneously produce anticancer activities while assisting, rather than inhibiting, virus
replication in cancer cells.
& 2015 Elsevier Inc. All rights reserved.
Introduction
Oncolytic virus (OV) therapy is a promising anti-cancer
approach that utilizes replication-competent viruses to target
and kill cancer cells while leaving normal cells unharmed. Many
OVs are being examined in clinical trials in the United States and
several are currently in phase III clinical trials, with approval of the
ﬁrst OV in North America expected in the near future (Bauzon and
Hermiston, 2014; Russell et al., 2012). This study is focused on
vesicular stomatitis virus (VSV, a rhabdovirus), which has been
used successfully against many malignancies in preclinical studies
[reviewed in (Hastie and Grdzelishvili, 2012; Russell and Peng,
2007; Russell et al., 2012)], and is currently in a phase I clinical
trial against hepatocellular carcinoma (trial NCT01628640). In
addition to its inherent oncoselectivity, VSV has a robust replica-
tion, a ubiquitous cell surface receptor, no risk of host cell
transformation, a lack of preexisting immunity in the general
population, and an 11-kb genome accommodating to the addition
of transgenes to improve its OV efﬁcacy [reviewed in (Hastie and
Grdzelishvili, 2012)].
Oncolytic abilities of viruses can be improved by creating
recombinant OVs that encode therapeutically beneﬁcial trans-
genes, including tumor suppressor genes. Restoration of “wild
type” (wt) p53 tumor suppressor activity has been exploited
extensively in various anticancer approaches and is known to
induce cell-cycle arrest, apoptosis, and senescence. Additionally,
more recently identiﬁed beneﬁcial p53 functions include regula-
tion of metabolism and promotion of enhanced antitumor immu-
nity (Cheok et al., 2011; Lane et al., 2010; Lowe et al., 2013). Not
surprisingly, virus-encoded p53 transgene expression has been
extensively explored in many replicating OV vectors, including
various adenovirus-based OVs (Geoerger et al., 2004; Heideman
et al., 2005; Idema et al., 2007; Koo et al., 2012; Mitlianga et al.,
2006; Wang et al., 2008; Yamasaki et al., 2012), vaccinia virus
(Hardwick et al., 2014), canary pox virus (Odin et al., 2001), and
VSV (Heiber and Barber, 2011).
Beyond the observed beneﬁts of p53 due to its anticancer
activities, it remains unclear how OV-encoded p53 transgene expres-
sion affects viral replication. Several studies showed that in normal
cells and some cancer cell lines, p53 inhibited virus replication via
enhanced type I Interferon (IFN) antiviral signaling (Dharel et al.,
2008; Lazo and Santos, 2011; Munoz-Fontela et al., 2005, 2011, 2008;
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Shin-Ya et al., 2005; Su et al., 2009; Takaoka et al., 2003; Yonish-
Rouach et al., 1991). In agreement with this, many viruses directly
target and inhibit p53 activities in infected cells [reviewed in (Sato
and Tsurumi, 2013)]. A previous study demonstrated strong antiviral
activities of p53 in normal mouse cells against VSV (Takaoka et al.,
2003; Yonish-Rouach et al., 1991). The study showed 30-fold higher
VSV yield in p53/ mouse embryonic ﬁbroblasts (MEFs) than in
wt MEFs, and that p53 knockout mice succumb to VSV infectionwith
100-fold increase in VSV found in sera when compared to wt mice
(Takaoka et al., 2003; Yonish-Rouach et al., 1991). Such activities of
virus-encoded p53 transgenes in cancer cells could dramatically
reduce the efﬁcacy of replicating OVs, including VSV.
Here we focus on VSV as a promising OV against pancreatic
ductal adenocarcinoma (PDAC) (Moerdyk-Schauwecker et al.,
2013; Murphy et al., 2012). PDAC is estimated to be the fourth
leading cause of cancer related-deaths in the United States and
treatment options to date are largely ineffective (Tarver, 2012).
Speciﬁc to PDAC, TP53 gene mutations occur in more than 75% of
patients and are shown to contribute to proliferation and even
drive metastasis through gain of function activities (Iacobuzio-
Donahue and Herman, 2014; Weissmueller et al., 2014). Previous
studies have shown that exogenous delivery of p53 sensitizes
PDAC to chemotherapy (Camp et al., 2013), treatment with
adenovirus encoding p53 sensitizes PDAC to radiation (Li et al.,
2013), and the use of small molecules like apigenin (King et al.,
2012) or mouse double minute 2 homolog (MDM2) inhibitors
(Azmi et al., 2010) can restore endogenous p53 function and slow
PDAC proliferation. Although VSV encoding p53 has never been
studied in PDAC cells, VSV-driven murine p53 gene expression
resulted in enhanced antitumor activities in vivo against mammary
adenocarcinoma (Heiber and Barber, 2011). The study, however,
did not examine the effect of murine p53 transgene expression on
antiviral signaling in cancer cells. Also, VSV encoding human p53
has never been studied before, and murine and human p53 may
have different activities (Horvath et al., 2007). Here, we sought to
examine how virus-encoded human p53 affects antiviral signaling
in human PDAC cells. To investigate this issue, we engineered
recombinant VSVs to encode human wt p53 or the recently
described chimeric p53-CC [tetramerization domain of p53 sub-
stituted with the coiled-coil (CC) domain from breakpoint cluster
region (Bcr) protein], which evades the dominant-negative activ-
ities of endogenously expressed mutant p53. Surprisingly, our data
show that both wt p53 and p53-CC downregulate cellular antiviral
responses in a variety of PDAC cell lines, and do so through
inhibition of the NF-κB pathway.
Results
Generation of novel recombinant VSVs encoding p53 and p53-CC
To investigate how p53 affects antiviral signaling in PDAC cells,
we engineered recombinant VSVs encoding human p53 (Fig. 1). In
addition to VSV encoding wt p53 (p53wt), we designed VSV
encoding the recently described chimeric p53-CC, which evades
the dominant-negative activities of endogenously expressed mut-
ant p53 (Okal et al., 2013). Transcriptionally active p53 binds to
diverse DNA targets as a tetramer. As does the C-terminus of
p53wt, the CC domain of the Bcr protein allows for formation of
antiparallel tetramers. However, unlike the C-terminus of p53wt,
the CC domain is no longer a binding site for endogenous mutant
p53 (Okal et al., 2013). As a result, the chimeric p53-CC protein was
shown to evade endogenous dominant-negative p53 and restore
p53wt activity better than p53wt in vitro in human ductal breast
epithelial, human breast adenocarcinoma, human epithelial cervi-
cal adenocarcinoma, and human non-small cell lung carcinoma
cell lines (Okal et al., 2013). To allow for visualization of p53
transgene expression in infected cells and discrimination between
virus-encoded and endogenous p53 gene expression, we fused the
N terminus of p53 (p53wt or p53-CC) to the C terminus of a near-
infrared ﬂuorescent protein, eqFP650 (herein called RFP) (Shcherbo
et al., 2007) (Fig. 1). The functionality of p53 fused to a ﬂuorescent
Fig. 1. Engineering recombinant VSV, sequencing rescued viruses, and virion
protein proﬁle. (A) Recombinant viruses were engineered using the VSV-ΔM51
backbone, with each transgene inserted between the VSV G and L protein sequence
using XhoI and NheI restriction sites. (B) Viral RNA genomes were puriﬁed and
cDNA was made and sequenced to conﬁrm the ΔM51 deletion and correct
transgene insertion. (C) Upper panel: Recombinant viruses were ampliﬁed, ultra-
puriﬁed, and total virion protein was analyzed using SDS-PAGE and Coomassie
stained to compare protein proﬁles. Lower panel: RNA was extracted from puriﬁed
virions and reverse transcribed into cDNA. Viral cDNA was PCR ampliﬁed using
primers ﬂanking XhoI and NheI restriction sites to conﬁrm transgene inserts.
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protein has been demonstrated previously for GFP (green ﬂuores-
cent protein) (Okal et al., 2013).
We designed all constructs in context of VSV-ΔM51, which has
a deletion of the methionine at amino acid position 51 (M51) of
the VSV M protein (Fig. 1A). There were three important reasons to
use the VSV-ΔM51 backbone. First, wt VSV cannot be utilized as
an OV due to its undesirable natural neurotoxicity through an
effective evasion of type I IFN mediated antiviral responses in
normal cells, including the CNS (Jenks et al., 2010; Johnson et al.,
2007). VSV M51 mutants lack neurotoxicity but retain good
oncolytic abilities (Ahmed et al., 2003; Brown et al., 2009; Ebert
et al., 2005; Stojdl et al., 2003; Trottier et al., 2007; von Kobbe et
al., 2000; Wollmann et al., 2010). In addition to safety, another
advantage of VSV-ΔM51 for p53 transgene expression is that,
unlike wt M protein, the ΔM51 M does not prevent cellular gene
expression in infected cells (Ahmed et al., 2003; Kopecky et al.,
2001; Stojdl et al., 2003). Therefore, VSV-ΔM51-encoded func-
tional p53 would be able to drive beneﬁcial expression of p53-
regulated anticancer genes. Finally, this system also allows us to
examine the effect of p53 expression on cellular antiviral
responses that would be otherwise silenced in the presence of
VSV wt M protein.
We designed and successfully rescued the VSVs, all carrying the
ΔM51 deletion and transgene sequences (Fig. 1A). The newly
created VSV-ΔM51-eqFP650 virus (herein called “VSV”) is a
“parental” genome for all other VSVs expressing the designed
transgenes: (1) VSV-p53wt, (2) VSV-p53-CC, (3) VSV-p53-CC/fs
where a frameshift (fs) prevents translation of the p53-CC poly-
peptide but allows for monitoring of any VSV attenuation caused
by the increased VSV genome length, (4) VSV-p53ΔODRD that
encodes p53, but without the C terminus of wt p53, and (5) VSV-
CC that express the CC domain of Bcr alone (no p53 sequences).
Viruses were rescued, ampliﬁed and ultra-puriﬁed. Genomic RNA
was isolated from puriﬁed virions and analyzed by RT-PCR. Partial
sequencing of cDNA conﬁrmed the presence of ΔM51 deletion as
well as correct transgene insertion and sequence (Fig. 1B and C).
Protein composition of the puriﬁed virions was examined using
SDS-PAGE, and all viruses, as expected, showed a similar banding
pattern indicating that transgene insertion did not produce any
unexpected alterations in viral genes (Fig. 1C). Importantly, no
genomic instability (e.g., loss of any transgene sequences) was
seen throughout our studies. All experiments were conducted
using ultrapure virion preparations.
Expression, localization and activity of VSV-encoded p53 variants
Most of the experiments were conducted using the human PDAC
cell line Suit2 (Iwamura et al., 1987). Suit2 cells, like PDAC cells in 75%
of patients, carry a TP53 mutation (Iacobuzio-Donahue and Herman,
2014; Weissmueller et al., 2014). Speciﬁcally, Suit2 cells were reported
to carry a common dominant-negative R273H mutation in TP53
(Iwamura et al., 1987), which we conﬁrmed by sequencing genomic
DNA (Table 3). The presence of this dominant-negative mutation in
TP53 allows for comparison of VSV-p53wt to VSV-p53-CC. Second,
based on our previous studies using a panel of human PDAC cell lines,
the Suit2 cell line represents the majority of the PDAC cell lines that
retain inducible type I IFN antiviral responses (Moerdyk-Schauwecker
et al., 2013). As such, the Suit2 cell line can be used to examine the
effect of p53 on antiviral responses.
To examine if p53 transgenes are expressed, Suit2 cells were
infected at MOI 5, total cell lysates were collected 8 h p.i. and
analyzed by Western blot. As shown in Fig. 2A, bands for the RFP-
p53 fusion proteins were detected in cells infected with the VSV-
p53wt, VSV-p53ΔODRD, and VSV-p53-CC viruses. As expected,
Fig. 2. Recombinant virus transgene expression and localization. (A) Suit2 cells
were infected at MOI 5 and lysed 8 h p.i. Expression of viral proteins and RFP-p53
fusion proteins were analyzed by Western blot. (B) Suit2 cells were infected at MOI
5 for 8 h, and ﬂuorescent microscopy was used to detect RFP-p53 (red) localization
in cells stained with Hoechst nuclear stain (blue) and HCS CellMask plasma
membrane stain (green).
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p53wt and p53-CC fused to RFP appear the same size on the blot
(approximately 73 kDa), while p53 with a truncated C terminus
encoded by VSV-p53ΔODRD, showed slight downshift on the blot.
This data conﬁrms virus-encoded p53 transgene expression.
Nuclear localization is required for p53 function as a transcrip-
tion factor. Full-length p53wt contains three nuclear localization
signals (NLS) in the C terminus: amino acid (aa) residues 305-322,
370–376, and 380–386. Although p53-CC was generated by trun-
cating p53wt (removal of aa residues 323 to 393), it still contains
one NLS (aa residues 305–322) and should localize in the nucleus
as well. Also, a previous study showed nuclear localization of GFP-
p53-CC protein expressed from a plasmid (Okal et al., 2013). To
examine nuclear localization of VSV-encoded p53 fused to RFP
(eqFP650), Suit2 cells were infected at MOI 5 and ﬂuorescent
confocal microscopy was conducted 8 h p.i. (Fig. 2B). Similar RFP-
p53 nuclear localization was seen in cells infected with VSV-
p53wt, VSV-p53ΔODRD, and VSV-p53-CC. As cell rounding occurs
following infection, the cytoplasmic area appears smaller and
difﬁcult to detect, compared to mock-infected cells (Fig. 2B),
However, the co-localization of RFP (red) and Hoechst (blue) can
be clearly seen for these 3 viruses, but not for VSV, VSV-CC and
VSV-p53-CC/fs (Fig. 2B). Interestingly, VSV-CC (no p53 sequences)
showed a distinct punctate localization for RFP-CC in the cyto-
plasm, that may be of interest for future studies regarding the
function of the CC domain of the BCR gene. In the two viruses
encoding transgenes without any NLS, VSV and VSV-p53-CC/fs,
RFP localization remained cytoplasmic, as expected. This data
conﬁrmed nuclear localization of viral-encoded p53.
Next, we wanted to examine if VSV-encoded p53wt and p53-CC
proteins were active as transcription factors in infected Suit2 cells.
Cells were mock treated or infected with VSV-p53wt, VSV-p53-CC, or
VSV-p53-CC/fs (no p53 production) at MOI 5 and total RNA was
collected 8 h p.i. and used for microarray analysis. Microarray results
were run though the Ingenuity pathway analysis (IPA) program,
which predicts which cellular signaling pathways are most affected
based on mRNA transcript levels following treatment. In Fig. 3A
(“virus compared to mock”), we compared p53-CC/fs-infected (no
p53 transgene is expressed), p53wt-infected, and p53-CC-infected
cells to mock-infected cells to determine pathways affected by VSV
infection, while in Fig. 3B (“virus compared to virus”) we compared
VSV recombinants expressing p53 transgenes to p53-CC/fs (no p53
transgene is expressed) to identify cellular pathways affected by the
p53 transgene expression during infection. Both analyses are shown
to discriminate between gene expression changes that can be
attributed to VSV infection and those attributed speciﬁcally to the
p53 transgene expression (the Y-axis in Fig. 3 shows the statistical
signiﬁcance for the identiﬁcation of the affected pathway). Fig. 3
shows that the IPA predicts that the p53 signaling pathway is in the
top ﬁve pathways affected for Suit2 cells infected with VSV-p53wt
and VSV-p53-CC, but not for VSV-p53-CC/fs (compared to mock-
treated cells) (Fig. 3A). Further, when comparing VSV-p53wt and
VSV-p53-CC to VSV-p53-CC/fs, the p53 signaling pathway is also
among the top ﬁve pathways affected (Fig. 3B). Interestingly, when
comparing VSV-p53wt to VSV-p53-CC, the p53 signaling pathway is
not highlighted as signiﬁcantly different, suggesting that the p53wt
and p53-CC proteins are both active and behave similarly, at least in
Suit2 cells under our experimental conditions (Fig. 3B). Further, we
examined changes in expression of many p53 target genes associated
with canonical p53 activity. Using a standard cut-off of at least a
2-fold change for mRNA levels, we identiﬁed many canonical p53
target genes that were up or downregulated by the p53 expressing
viruses, for example: apoptosis [BCL2-Associated X Protein (BAX) and
B-Cell CLL/Lymphoma 2 (BCL2)], cell proliferation [Mouse Double
Minute 2 (MDM2)], cell cycle arrest [Cyclin-Dependent Kinase
Inhibitor 1A (CDKN1A/P21)], angiogenesis inhibition [Thrombospon-
din 1 (THBS1)), and DNA repair (Topoisomerase (DNA) II Binding
Protein 1 (TOPB1)] (see Supplemental Table 2 for a complete list of
affected genes).
If virus-encoded p53wt and/or p53-CC are active, we expected
them to enhance VSV cytotoxicity in cancer cells. Suit2 cells were
mock treated or infected MOI 0.00002, 0.002, 0.1 and 1 with VSV,
VSV-p53wt, VSV-p53-CC, or VSVp53-CC/fs and cell viability was
examined at 1, 24, 48, and 96 h p.i. using an MTT cell viability
assay. As shown in Fig. 4 for MOI 0.002 and 0.00002, although no
difference in cell killing between all viruses was seen at the higher
MOI (a similar result was for MOI 0.1 and 1, data not shown), at the
lower MOI we observed signiﬁcantly more oncolysis by the VSVs
expressing p53wt or p53-CC transgene, compared to VSV or VSV-
p53-CC/fs (at 48 and 96 h p.i.). The inability of virus-encoded
p53wt and p53-CC to enhance oncotoxicity of VSV at higher MOIs
Fig. 3. Top 5 canonical pathways affected in infected Suit-2 cells. Cells were mock treated or infected with VSV-p53wt, VSV-p53-CC, or VSV-p53-CC/fs at MOI 5. Total RNA
was extracted 8 h p.i. Microarray data that indicated more than a 2-fold change in cellular mRNA transcript levels in VSV-p53wt, VSV-p53-CC, or VSV-p53-CC/fs infected cells
(compared to mock or to VSV-p53-CC/fs) was analyzed with Ingenuity pathway analysis software and the top 5 canonical pathways are shown for (A) virus- to mock-treated
comparison and (B) virus to virus comparison.
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may be due to strong cytotoxic effect of VSV itself masking the
effect of the transgene.
Together, our results show that both VSV-p53wt and VSV-p53-
CC are able to successfully direct expression of the designed p53
transgene, and that the gene products localize in the nucleus and
are active as transcription factors, up or downregulating known
p53 targets. Moreover, the virus-encoded p53wt and p53-CC
enhance oncotoxicity of VSV, at least under some of our experi-
mental conditions.
p53wt and p53-CC suppress the type I IFN response in Suit2 cells
Using the transcriptome proﬁle of Suit2 cells following mock
treatment or infection with VSV-p53wt, VSV-p53-CC, or VSV-p53-
CC/fs, we analyzed expression levels for genes associated with
type I and type II IFN signaling pathways using the Ingenuity
pathway analysis. Fig. 5 provides a visual interpretation of at least
2-fold up (red) or downregulation (green) of genes that were
identiﬁed (Fig. 5A shows the data for cells infected with VSV-p53-
CC/fs compared to mock-infected cells, while Fig. 5B compares
VSV-p53wt- to VSV-p53-CC/fs-infected cells). Table 1 is a quanti-
tative list of the same data. In general, our data show that all the
tested VSV induce signiﬁcant antiviral responses. However, con-
trary to an expected enhancement of antiviral signaling by p53,
when we compare Suit2 cells infected with VSV-p53wt or VSV-
p53-CC vs. cells infected with p53-CC/fs (no p53 transgene is
expressed), the type I IFN signaling response was dramatically
attenuated (Table 1). Speciﬁcally, while there was a 291.10-fold
increase in IFN-β transcripts by VSV-p53-CC/fs (the recombinant
VSV that does not express p53) compared to mock-treated cells,
only 25.24-fold and 4.56-fold increases in IFN-β transcript levels
were observed for VSV-p53wt or VSV-p53-CC, respectively. Impor-
tantly, the transcriptome also showed that p53wt and p53-CC
reduced virus-mediated expression of several key cellular antiviral
proteins, including Myxovirus resistance 1 (Mx1), 20-50-oligoade-
nylate synthetase-like (OASL), Janus kinase 2 (JAK2), signal trans-
ducer and activator of transcription 1 (STAT1), and interferon-
induced protein with tetratricopeptide repeats 1 (IFIT1) (Fig. 5 and
Table 1). Also, infection with VSV-p53wt and VSV-p53-CC caused
upregulation of the suppressor of cytokine signaling (SOCS1) that
is known to inhibit STAT1 antiviral signaling activity (Song and
Shuai, 1998).
To conﬁrm this surprising effect of p53 inhibition of type I IFN
signaling that was seen with the microarray (Table 1), Suit2 cells
were mock treated or infected with VSV-p53wt, VSV-p53-CC, or
VSV-p53-CC/fs at MOI 5 and total lysates were collected at 8, 12,
and 18 h p.i. Western blot conﬁrmed the expression of the p53wt
and p53-CC as well as viral proteins at all time points (Fig. 6).
Interestingly, there did not appear to be any differences in viral
protein accumulation between viruses. Also, the phosphorylation
of interferon regulatory factor 3 (IRF3) did not appear different
between viruses, suggesting that cellular detection of viruses was
similar regardless of expression of p53 transgenes. However, in
agreement with the microarray data, in cells infected with VSV-
p53wt or VSV-p53-CC, there was signiﬁcantly reduced phosphor-
ylation of STAT1, which is dependent on IFN production in infected
cells. This result conﬁrms that the virus-encoded p53 inhibits,
rather than enhances, antiviral responses in VSV-infected
Suit2 cells.
p53wt and p53-CC suppress type I IFN responses through inhibition of
the NF-κB pathway
To further investigate the downregulation of IFN signaling by
VSV-encoded p53wt and p53-CC, we used the Suit2 cell line
transcriptome data to analyze potential effects of p53wt or p53-
CC on NF-κB signaling pathways. NF-κB is known to upregulate
early antiviral responses including type I IFN expression (Wang
et al., 2010) and can be directly or indirectly inhibited by p53
(Ak and Levine, 2010; Culmsee et al., 2003; Heyne et al., 2013;
Kawauchi et al., 2008; Murphy et al., 2011; Webster and Perkins,
1999). The Ingenuity pathway analysis detected downregulation of
key NF-κB signaling pathway proteins (Fig. 7, Table 2). Impor-
tantly, the NF-κB subunit RelA, known to be critical for induction
of IFN-β at early time points of infection, was downregulated by
both VSV-p53 and VSV-p53-CC (Table 2). Additionally, we found
downregulation of TBK1, a cellular protein that links the NF-κB
and IRF3 pathways to IFN production (Fitzgerald et al., 2003;
Hiscott et al., 2003). Also, there was a 51.99-fold increase in IL-1, an
NF-κB induced cytokine, when cells were infected with VSV-p53-
CC/fs, but no change after VSV-p53wt or VSV-p53-CC infection
VSV
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Fig. 4. Suit2 cell viability following infection with VSV recombinants. Suit2 cells were mock treated or infected with VSV, VSV-p53wt, VSV-p53-CC, or VSV-p53-CC/fs viruses
at MOI 0.002 or 0.00002. Cell viability was analyzed 1, 24, 48, and 96 h p.i. by MTT cell viability assay and is expressed as a percentage of mock-treated cells. All MTT assays
were done in triplicate, and the data represent the means 7SEM.
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(Table 2). This data suggests that the NF-κB pathway is strongly
downregulated by expression of the p53 transgenes.
To test the hypothesis that VSV-encoded p53wt and p53-CC
inhibit type I IFN responses via inhibition of NF-κB signaling, we
conducted an experiment combining VSV infection with treatment
of cells either with IKK-2 inhibitor VIII (to speciﬁcally prevent
NF-κB activation) or JAK1/JAK2 inhibitor Ruxolitinib (to directly
inhibit type I IFN-mediated signaling). Thus, if virus-encoded p53
inhibits type I IFN signaling in Suit2 cells via NF-κB inhibition, we
would expect to see that (i) IKK-2 inhibitor VIII would have a
similar effect on antiviral signaling as Ruxolitinib, and that (ii) the
combination of IKK-2 inhibitor VIII with VSV-p53-CC/fs would
produce a similar inhibiting effect on antiviral signaling as VSV-
p53wt or VSV-p53-CC alone. Cells were ﬁrst mock treated or
infected with VSV-p53wt, VSV-p53-CC, or VSV-p53-CC/fs at MOI
10, then mock treated (DMSO) or treated with each inhibitor for
8 h. RT-PCR results shows that, compared to mock-treated cells,
there was upregulation of MxA, OAS, IFN-β, and IkB-α transcripts
by VSV-p53-CC/fs (Fig. 8). And, consistent with the transcriptome
data, there was downregulation of all these four cellular genes by
VSV-p53wt and VSV-p53-CC (in comparison to VSV-p53-CC/fs). In
agreement with our hypothesis, treatment of cells with IKK-2
inhibitor VIII mimicked inhibition of IFN pathway signaling simi-
larly to Ruxolitinib for all 3 viruses. Importantly, administration of
the IKK-2 inhibitor VIII inhibited upregulation of antiviral gene
transcripts seen by VSV-p53-CC/fs infection, bringing down the
expression levels to those induced by VSV-p53wt or VSV-p53-CC
alone (Fig. 8). This data suggests that type I IFN signaling in Suit2 is
under direct control of NF-κB, and that VSV-encoded p53wt or
p53-CC downregulate type I IFN responses via inhibition of NF-κB
pathway.
p53-mediated suppression of type I IFN response in other PDAC cells
lines
Next, we wanted to see if the inhibition of antiviral signaling by
VSV-encoded p53 is observable in other PDAC cell lines, and if the
cellular endogenous p53 status plays a role in the observed inhibi-
tion. We chose three PDAC cell lines that retain virus-mediated type I
IFN responses, T3M4, Capan2, and ASPC-1 (Moerdyk-Schauwecker et
al., 2013). Additionally, we chose one control cell line, a “normal”
(non-malignant) human pancreatic ductal epithelia cell line, HPDE.
Using genomic DNA, we analyzed the p53 status of each cell line
with Ion Ampliseq Hotspot analysis. The TP53 mutations identiﬁed
Fig. 5. Microarray results applied to the Ingenuity IFN signaling pathways. The Ingenuity pathway analysis identiﬁed IFN pathway related transcripts that were differentially
expressed in Suit2 cells. The cellular genes are shown with more than a 2-fold change in VSV-p53wt, VSV-p53-CC, or VSV-p53-CC/fs infected cells (compared to mock or to
VSV-p53-CC/fs). (A) Cells infected with VSV-p53-CC/fs are compared to mock-infected cells. (B) Cells infected with VSV-p53wt are compared to VSV-p53-CC/fs-infected cells.
Red indicated upregulated transcripts while green represents downregulated transcripts.
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by Ion Ampliseq for all cell lines were independently conﬁrmed using
PCR ampliﬁcation and sequencing of a region of genomic DNA
between TP53 exons 5 and 9, where most p53 mutations occur
(Table 3). As expected for most human PDACs, all PDAC cell lines
contained mutations in the TP53 gene. The R273H mutation for Suit2
and Capan-2 is a known dominant-negative mutation, while the
Y220C mutation for T3M4 is shown only to have moderate
dominant-negative activity. For ASPC-1, we identiﬁed an early frame-
shift mutation (C135fs) that results in a small truncated protein
product that could not be detected by Western blot analysis. As
expected for non-malignant cell line, HPDE had a wt TP53 gene
sequence.
To investigate how VSV-encoded p53 expression affects anti-
viral signaling in these cell lines, cells were mock treated or
infected with VSV-p53wt, VSV-p53-CC, or VSV-p53-CC/fs at MOI
5 and total RNA was isolated 8 h p.i. and analyzed by RT-PCR for
speciﬁc gene expression levels. As was seen previously in Suit2,
there was p53-mediated downregulation of transcripts associated
with type I IFN as well as NF-κB signaling in T3M4, Capan-2, and
ASPC-1 (Fig. 9). In particular, both p53wt and p53-CC reduced
expression of the IFN-β mRNA at 8 h p.i. This result suggests that
the observation of virus-encoded p53 effect on type I IFN signaling
is not limited only to Suit2 cell line or the R273H mutation in TP53.
The results in Fig. 9 conﬁrm our previous ﬁndings that a non-
malignant pancreatic cell line HPDE (resistant to VSV) constitu-
tively expresses MxA, OAS, IFN-α, IFN-β (Moerdyk-Schauwecker
et al., 2013). Importantly, expression of p53 encoded by VSV-
p53wt or VSV-p53-CC did not inhibit type I IFN or NF-κB signaling
in HPDE. This suggests that the observed p53-mediated inhibition
of IFN antiviral signaling could be limited to malignant PDAC cells
(Fig. 9).
VSV-p53 recombinants retain their oncoselectivity and are attenuated
in non-malignant pancreatic ductal cells
As patient safety is a major concern for treatment with
replication-competent viruses, it is imperative that any virus-
encoded transgene not cause the virus to lose oncoselectivity
and attenuation in normal cell types. The data above suggests that
VSV-p53wt or VSV-p53-CC do not inhibit IFN-β signaling in HPDE
as they do in PDAC cells. To further examine whether p53
transgene expression may result in the loss of oncoselectivity of
VSV recombinants, the same virus stocks of VSV, VSV-p53wt, VSV-
p53-CC, or VSV-p53-CC/fs were titrated on HPDE, Suit2, T3M4,
Capan-2, and ASPC-1 cells using plaque assay (Fig. 10A). All viruses
showed cell-speciﬁc titers that were at least 2 logs lower in HPDE
cells compared to PDAC cell lines, suggesting similar levels of
attenuation in HPDE cells, regardless of p53 or p53-CC expression
(Fig. 10A). Further, the cell lines were mock treated or infected at
MOI 0.1 or 10, and cell viability was measured with MTT assay
5 days p.i. At MOI 0.1 (Fig. 10B), HPDE showed limited cell death
with all tested viruses. Compared to the PDAC cell lines, where
Capan-2 and ASPC-1 showed almost no viable cells and T3M4 and
Suit2 show some resistance, the p53 transgene does not appear to
increase cell killing of HPDE. Even more, at MOI 10 HPDE showed
only 50 percent cell viability when infected with VSV, and 75
percent cell viability when infected with VSV-p53wt, VSV-p53-CC,
or VSV-p53-CC/fs (Fig. 10C). Compared to the PDAC cell lines,
Table 1
Effect of virus infection on interferon signaling pathways.
Symbol Entrez Gene
#
Fold induction (virus compared to
mock)
Fold induction (virus compared to virus)
VSV-p53-CC/
fs
VSV-
p53wt
VSV-p53-
CC
VSV-p53wt toVSV-p53-
CC/fs
VSV-p53-CC to VSV-p53-
CC/fs
VSV-p53-CC to VSV-
p53wt
Interferon signaling
IFNB1 3456 291.10 25.24 4.56 11.53 63.80 5.53
IFN Gamma (IL28A) 282616 476.72 173.02 62.15 2.76 7.67 2.78
IFNAR1 3454 2.07 3.36 3.87 2.18 2.51 –
IFNAR2 3455 2.74 2.96 3.21 5.12 3.22 –
IFNGR1 3459 5.90 7.13 10.35 3.98 5.54 –
IFNGR2 3460 2.16 2.24 2.14 4.84 4.61 –
JAK2 3717 22.74 5.30 3.26 5.55 6.98 –
STAT1 6772 23.33 7.92 4.35 2.18 7.30 –
STAT2 6773 8.08 2.59 – 3.11 3.79 –
IRF9 10379 6.08 2.84 2.05 2.14 2.96 –
Inhibitor of Jak/Stat
signaling
SOCS1 8651 2.24 10.34 13.74 9.32 12.38
PTPN2 (TCPTP) 5771 2.03 4.35 4.61 2.14 2.27
PIAS1 8554 – 3.46 3.38 2.78 2.79
Interferon β/γ Stimulated
genes
MX1 4599 71.99 37.77 27.59 – 2.61 –
OASL 8638 170.50 59.90 29.63 2.85 5.73 2.02
IRF1 3659 21.52 7.83 4.21 3.39 7.51 2.21
IFI35 3430 8.03 3.74 2.43 2.15 3.30 –
IFIT1 3434 71.80 19.34 9.30 3.71 7.72 2.08
IFIT3 3437 74.99 24.06 26.15 3.12 2.87 –
PSMB8 5696 3.40 2.56 – – 2.49 –
Downstream of IRF1
BAX 581 – 2.46 – 4.11 3.24 –
BAK1 578 – 2.64 – 2.50 – 2.94
BCL2 596 – – 2.61 – 3.30 2.05
RELA 5970 - 2.17 2.66 2.91 2.62
Ingenuity pathway analysis of Interferon Signaling in Suit2 cells. Cellular transcripts were reported if they were more than 2-fold up or downregulated 8 h p.i. Cellular
transcript proﬁles after infection of each virus, VSV-p53-CC/fs, VSV-p53wt, or VSV-p53-CC, are compared to mock as well to each other.
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where Suit2, Capan-2, and ASPC-1 show no viable cells and T3M4
remains resistant, this data suggests that HPDE cells retain
resistance to VSV regardless of p53 or p53-CC expression.
Together, our data show that VSV recombinants encoding p53
retain their oncoselectivity and are attenuated in non-malignant
cells.
Discussion
In the present study, novel VSVs encoding functional human
p53 or the chimeric p53-CC have been generated. Our study is the
ﬁrst to date to conduct a global analysis of PDAC mRNA expression
following infection with any VSV. Based on this analysis and other
experiments, we report p53-mediated inhibition of antiviral sig-
naling. Our results suggest that virus-encoded p53 expression can
simultaneously produce anticancer activities while assisting,
rather than inhibiting, viral replication in PDAC cells.
Our data is in direct contrast to previous reports that p53
enhances type I IFN signaling pathway in normal cells and some
cancer cell lines (Dharel et al., 2008; Lazo and Santos, 2011;
Munoz-Fontela et al., 2005, 2011, 2008; Shin-Ya et al., 2005; Su
et al., 2009; Takaoka et al., 2003; Yonish-Rouach et al., 1991). There
are several potential reasons for the discrepancy between our
results in human PDAC cells and previous results in other cell
types: (1) differences between normal and cancer cells (and
between different cancer cell types) in antiviral signaling, (2) con-
stitutive activation of NF-κB pathway in a majority of PDACs, and
(3) different timing and level of expression for VSV-encoded p53
in our study, and constitutively expressed p53 transgenes in other
studies.
The unexpected inhibition of antiviral signaling by p53 can be
explained by dysregulation of type I IFN signaling in cancer cells. In
many cancer cell types, speciﬁc genes associated with type I IFN
signaling are transcriptionally downregulated or functionally inactive
(Balachandran and Barber, 2004; Marozin et al., 2008, 2010; Moussavi
et al., 2010; Zhang et al., 2010). Also, type I IFNmediated responses can
be inhibited by MEK/ERK signaling, which is often upregulated in
cancer cells (Noser et al., 2007), or by epigenetic silencing of IFN
responsive transcription factors IRF7 or IRF5 (Li and Tainsky, 2011).
Although all tested PDAC cell lines retain at least partially functional
type I IFN signaling (Moerdyk-Schauwecker et al., 2013), it is likely that
they have some dysregulation of this pathway, as type I IFN responses
are generally anti-proliferative and pro-apoptotic (Stojdl et al., 2000;
Vitale et al., 2007). Such dysregulation may result in the inability of
p53 to positively affect antiviral signaling in PDAC cells.
The NF-κB pathway has been previously shown to be con-
stitutively active in a majority of PDACs (Carbone and Melisi,
2012). Such abnormal activation of NF-κB plays a major role in
tumor development maintaining expression of cellular genes that
promote cell growth, proliferation and survival. Our data suggest
that VSV-encoded p53wt or p53-CC downregulate antiviral
responses via inhibition of NF-κB (as illustrated in Fig. 11). As
was shown previously, NF-κB is crucial for early IFN-β expression
and resistance to virus replication (Wang et al., 2010). Our results
are in agreement with previous studies demonstrating inhibition
of NF-κB pathway by p53 via various mechanisms, including
prevention of NF-κB nuclear translocation through upregulation
of NF-κB inhibitor, IκBα (Shao et al., 2000), competition for
common transcription cofactors (p300 and cAMP response
element-binding protein (CBP) (Culmsee et al., 2003), and/or
directly binding to NF-κB (RelA subunit p65) to disrupt its
binding to DNA (Kawauchi et al., 2008). While beyond the scope
of this study, the exact mechanism of p53-mediated NF-κB
inhibition in the tested PDAC cell lines could be determined in
the future.
Finally, the constitutively expressed p53 transgenes in other
studies are likely stabilized and activated rapidly in response to
viral infection, while VSV-mediated expression of p53 in our study
probably takes longer. From our own observation, even following
high MOI infection, VSV-encoded RFP was not visible until at least
5 h p.i. (data not shown), suggesting that expression of virus-
encoded p53 and its effects occur after initial virus detection and
stimulation of antiviral signaling.
Interestingly, VSV expressing p53 (wt or p53-CC) remained
attenuated in non-malignant pancreatic ductal cell line HPDE,
suggesting that these novel OVs would retain their safety in vivo.
Future studies with VSVs expressing human p53 in animal models
will determine if the oncoselective phenotype seen in PDAC cell
lines is also observed in vivo. As beneﬁcial p53 functions include
promotion of enhanced antitumor immunity (Lowe et al., 2013), to
fully examine the anticancer abilities of VSV-p53 or VSV-p53-CC,
the viruses need to be tested in an immunocompetent system.
Unfortunately, the current design of our VSV-p53 recombinants
complicates this task, as they encode human p53. Also, in our
previous study all tested mouse PDAC cell lines had defective type
I IFN signaling (Hastie et al., 2013), so our current in vivo mouse
model of PDAC cannot be used to comprehensively test the novel
VSV-p53 recombinants for their effect on antiviral signaling in
those mouse PDAC cells. However, our data are in agreement with
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Fig. 6. Western blot analysis following VSV infection in Suit2 cells. Cells were
infected with VSV-p53wt, VSV-p53-CC, or VSV-p53-CC/fs at MOI 5. Cell lysates
were collected at the indicated time points and analyzed by Western blot.
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Heiber and Barber (2011) who demonstrated that VSV encoding
mouse p53 is not attenuated in vitro, but highly attenuated in
normal tissues in vivo, and that in vivo treatment of mice results in
enhanced tumor killing through stimulated antitumor immunity
(Heiber and Barber, 2011). It should be noted that analysis of
murine and human p53 response element consensus sequences
show many differences between murine and human p53, suggest-
ing that caution should be taken when generalizing about the
similarity of regulation of the p53 pathway between humans and
rodents (Horvath et al., 2007). Nevertheless, our present data and
the previous study using VSV encoding mouse p53 in vivo (Heiber
and Barber, 2011) both show VSV-p53 as a promising OV. Sig-
niﬁcantly, a recent clinical trial using vaccinia virus encoding p53
has also shown enhanced oncolytic efﬁcacy in clinical trials
through stimulation of an antitumor immune response (Hardwick
et al., 2014). None of these previous studies has examined total gene
expression in cancer cells in response to virus infection, but our data
using VSV provides evidence of a new mechanism for enhanced
oncolytic efﬁcacy of viruses encoding p53 that will be important for
future studies as OVs move forward in clinical application.
Materials and methods
Cell lines
The human PDAC cell lines used in this study were: AsPC-1
(ATCC CRL-1682), Capan-2 (ATCC HTB-80), Suit2 (Iwamura et al.,
1987) and T3M4 (Okabe and Yamaguchi, 1983). A non-malignant
human pancreatic duct epithelial (HPDE) cell line was previously
generated by introduction of the E6 and E7 genes of human
papillomavirus 16 into normal adult pancreas epithelium. HPDE
retains a genotype similar to pancreatic duct epithelium and is
non-tumorigenic in nude mice (Furukawa et al., 1996). The baby
hamster kidney BHK-21 ﬁbroblasts (ATCC CCL-10) were used to
grow viruses. Suit2 cells were maintained in Dulbecco’s modiﬁed
Eagle’s medium (DMEM, Cellgro); AsPC-1, Capan-2, and T3M4 in
RPMI 1640 (HyClone); BHK-21 in modiﬁed Eagle’s medium (MEM,
Cellgro); HPDE in Keratinocyte-SFM (K-SFM, Gibco) without
serum. All cell growth media (except for K-SFM) were supplemen-
ted with 9% fetal bovine serum (FBS, Gibco), 3.4 mM L-glutamine,
100 U/ml penicillin and 100 μg/ml streptomycin (HyClone). MEM
was further supplemented with 0.3% glucose (w/v). Cells were
kept in a 5% CO2 atmosphere at 37 1C. For all experiments, PDAC
cell lines were passaged no more than 10 times. After receipt, the
human origin of all PDAC cell lines was conﬁrmed by partial
sequencing of KRAS and actin. As expected, all PDAC cell lines (but
not HPDE cells) had a mutation in KRAS, as is typical for PDACs
(data not shown).
Generation of novel recombinant VSVs
A plasmid containing cDNA copy of recombinant VSV-XN2-ΔM51
genome (VSV Indiana serotype) (Lawson et al., 1995; Wollmann et al.,
2010) was kindly provided by Jack Rose (Yale University). A pUC57
plasmid encoding near-infrared ﬂuorescent protein eqFP650 was
designed based on the published eqFP650 sequence (accession
HQ148301) (Shcherbo et al., 2010) and was purchased from Genscript.
The pUC57-eqFP650 plasmid contains a T7 promoter, a XhoI site, and a
Kozak consensus sequence upstream of the eqFP650 start site
(TAATACGACTCACTATAGGGAGACTCGAGCCACCATG). Downstream of
the eqFP650 coding sequence containing a BspEI site there are two
stop sites followed by a NheI site (CAGCTCCGGATAATAGCTAGC).
Plasmids “GFP-p53” (Cat. no. 12091) (Boyd et al., 2000) and “HA-
NF-kB signaling pathway
VSV-p53wt to VSV-p53-CC/fs VSV-p53-CC/fs to Mock
Fig. 7. Microarray results applied to the Ingenuity NF-κB signaling pathway. The Ingenuity pathway analysis identiﬁed NF-κB pathway related transcripts that were
differentially expressed in Suit2 cells. The cellular genes are shownwith more than a 2-fold change in VSV-p53wt, VSV-p53-CC, or VSV-p53-CC/fs infected cells (compared to
mock or to VSV-p53-CC/fs). (A) VSV-p53-CC/fs to mock. (B) VSV-p53wt to VSV-p53-CC/fs. Red indicated upregulated transcripts while green represents downregulated
transcripts.
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tagged BCR” (Cat. no. 38189) were purchased from Addgene. Plasmids
were ampliﬁed in JM109 Escherichia coli. Selection for colonies
containing VSV-XN2-ΔM51 or HA-tagged BCR plasmids was done
with 50 μg/ml of ampicillin, and GFP-p53 plasmid with 50 μg/ml of
kanamycin. To generate VSV-ΔM51-eqFP650, pUC57-eqFP650 was
digested using XhoI and NheI restriction enzymes, and the fragment
was inserted into a XhoI-NheI digested VSV-XN2-ΔM51 plasmid. To
generate VSV plasmids with eqFP650-p53, p53 sequence was ﬁrst
inserted into pUC57-eqFP650 plasmids, and then eqFP650-p53 was
cloned into VSV-XN2-ΔM51 plasmid. To generate the p53 gene insert,
the p53 sequence from the GFP-p53 plasmid was PCR ampliﬁed using
primers VG283 and VG284 (Supplemental Table 1). To generate the
TP53ΔODRD insert, the TP53ΔODRD sequence from the GFP-p53
plasmid was PCR ampliﬁed using primers VG283 and VG285. To
generate the CC insert, the CC sequence from the HA-tagged BCR
plasmid was PCR ampliﬁed using primers VG286 and VG292. To
Table 2
Effect of virus infection on NF-κB signaling pathway.
Symbol Entrez gene # Fold induction (virus compared to
mock)
Fold induction (virus compared to virus)
VSV-p53-CC/
fs
VSV-
p53wt
VSV-p53-
CC
VSV-p53wt to VSV-p53-CC/
fs
VSV-p53-CC to VSV-p53-CC/
fs
VSV-p53-CC to VSV-
p53wt
Extracellular space
IL1A 3552 51.99 – – 42.09 45.11 –
TNFSF13B (BAFF) 10673 19.03 2.10 – 5.78 9.56 –
TGFA 7039 2.39 – – 3.06 2.12 –
BMP4 652 3.75 3.00 2.43 – – –
NFKB activation/repression
Cytoplasm
IL1R1 3554 – 3.48 – 3.52 – 3.45
PEL1 57162 4.52 2.77 – 3.81 3.97 –
IRAK1 3654 2.42 – – 2.24 – –
TNFAIP3 (A20) 7128 86.24 4.87 4.18 14.14 16.47 –
MAP3K7 (TAK1) 6885 2.38 2.25 4.36 2.35 2.14 –
EIF2AK2 (PKR) 5610 2.05 2.68 2.19 – 2.04 –
TAB2 23118 – 3.67 3.77 2.09 2.15 –
CD40 958 – 4.09 3.04 – – –
RAS 3845 2.41 5.01 4.17 4.09 2.29 –
ARAF 369 2.28 3.17 3.17 – – –
PIK3CA (PI3K) 5290 – – 2.17 – 2.48 –
TNFRSF1A
(TNFR)
7132 3.45 2.40 4.01 – – –
TANK 10010 – 2.58 7.23 2.38 4.10 2.80
FADD 8772 2.47 6.01 6.39 2.44 2.59 –
MAP3K8 (COT) 1326 8.48 3.86 2.24 2.56 4.83 –
AKT2 208 2.05 2.29 2.16 – – –
PLCG1 5335 – 2.01 – 3.00 – –
TRAF1 7185 2.76 – – – 2.12 –
TNIP1 (ABIN1) 10318 10.76 – – 5.83 11.58 –
CARD10 (BIMP1) 29775 5.19 2.22 – 11.54 7.04 –
MAP2K6 (MKK6) 5608 – 2.20 2.02 2.02 – –
Nuclear
AZI2 (NAP1) 64343 2.24 2.46 3.35 2.40 2.12 –
(TBK1) NAK 29110 – 2.07 2.82 2.92 3.98 –
CREBBP 1387 – – 2.57 2.48 3.41 –
EP300 (p300) 2033 – 3.63 4.43 2.94 3.72 –
GSK3B 2932 – 2.34 – 2.33 – –
CSNK2A1 1457 2.65 3.34 3.09 2.91 2.38 –
Cytoplasm/nuclear
RelA (p65) 5970 – 2.17 2.66 2.91 2.62 –
RelB 5971 6.39 2.04 – 3.13 5.10 –
NFKB1 (p50) 4790 3.69 3.97 2.03 – – –
NFKB2 (p52) 4791 2.07 – – 4.24 6.21 –
NFKB1A (IkB) 4792 23.41 – – 12.47 20.68 –
IKBKB (IKKB) 3551 – 2.20 2.20 2.20 2.32 –
IKKb (IKBKB) 3551 – 2.20 2.20 2.20 2.32 –
Ingenuity pathway analysis of NF-κB Signaling in Suit2 cells. Cellular transcripts were reported if they were more than 2-fold up or downregulated 8 h p.i. Cellular transcript
proﬁles after infection of each virus, VSV-p53-CC/fs, VSV-p53wt, or VSV-p53-CC, are compared to mock as well compared to each other.
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Fig. 8. Effect of a NF-κB signaling inhibitor on infected Suit2 cells. Cells were mock
treated or infected with VSV-p53wt, VSV-p53-CC, or VSV-p53-CC/fs at MOI 10,
followed by mock treatment (DMSO) or treatment with 8 μM IKK-2 Inhibitor VIII or
2.5 μM Ruxolitinib for 8 h. Total RNA was extracted, reverse transcribed and
analyzed by PCR for the indicated genes.
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generate TP53-CC, the TP53ΔODRD sequence from the GFP-p53
plasmid was PCR ampliﬁed using primers VG283 and VG293 and
the CC sequence from the HA-tagged BCR plasmid was PCR ampliﬁed
using primers VG288 and VG292. The TP53ΔODRD and CC PCR
products were used for overlapping PCR along with primers VG283
and VG292. All forward and reverse primers, except those used for
overlap PCR, contained a BspEI site and a NheI site, respectively. All
PCR products were digested sequentially with NheI and BspEI
restriction enzymes and ligated into the NheI-BspEI digested
pUC57-eqFP650 vector fragment to generate pUC57-eqFP650-
TP53wt, pUC57-eqFP650-TP53ΔODRD, pUC57-eqFP650-CC, and
pUC57-eqFP650-TP53-CC. To create the pUC57-eqFP650-TP53-CC/fs,
the pUC57-eqFP650-TP53-CC plasmid was digested with BspEI, ﬁlled
in with T4 DNA polymerase (NEB, MO203S), and re-ligated. All
pUC57 plasmids containing the eqFP650-fusion genes were double
digested with XhoI and NheI restriction enzymes and the inserts
were ligated into the XhoI-NheI digested VSV-XN2-ΔM51 plasmid.
All plasmids were sequenced to conﬁrm the ΔM51 deletion and all
gene insertions (primers listed in Supplemental Table 1). Recombi-
nant VSVs were rescued as previously described (Grdzelishvili et al.,
2005), which is a modiﬁcation of the original protocol in (Lawson
et al., 1995). VSV stocks were prepared using BHK-21 cells infected at
a multiplicity of infection (MOI) 0.005 and incubated at 37 1C in
MEM-based medium containing 5% FBS. Virus-containing medium
was collected at 24 h post infection (h p.i.) and centrifuged at
4000 g for 10 min at 4 1C to remove large cellular debris. Virus
was puriﬁed by the method of Kalvodova et al. with slight
modiﬁcations described previously (Hastie et al., 2013; Kalvodova
et al., 2009). Cell speciﬁc viral titers were obtained using plaque
assay. Following virus rescue, ampliﬁcation, and puriﬁcation, RNA
was isolated and sequenced conﬁrming the ΔM51 deletion and
correct transgene insertions.
Confocal imaging for virus-expressed transgene localization
Suit2 cells were seeded in borosilicate glass chamber slides
(Labtek, Cat. No. 155411) to be approximately 80% conﬂuent in 24 h.
Cells were mock treated or infected at MOI 5 in growth medium
without FBS. Virus-containing medium was aspirated 1 h p.i. and
replaced with growth medium containing 5% FBS. At 8 h p.i., growth
media was aspirated and cells were stained with 1 μM Hoechst dye
(nuclear stain) and HCS CellMask (plasma membrane and cytoplas-
mic stain) (Life Technologies, H32714) for 30 min. Growth media
was aspirated, cells were washed twice with PBS, then media with
5% FBS was added and cells were used for confocal imaging
(Olympus FluoView 1000) using ﬁlters for DAPI/Hoechst (blue),
FITC (green), and Alexa Fluor 568 (red).
RNA microarray analysis
Cells (in triplicate) were seeded in 6-well plates so that they
reached approximately 80% conﬂuence at 24 h. Cells were mock
treated or infected with VSVs at MOI 5. Cellular RNA was extracted
with TRIzol (Life Technologies) per the manufacturer protocol with
slight modiﬁcation. In brief, following the ﬁrst phase separation, the
aqueous layer was transferred to a new tube. Then, 500 μl of TRIzol
and 100 μl of chloroform were added and phase separation was
repeated. Isolated RNA was run on a Bioanalyzer 2100 (Agilent) to
check for purity. RNA integrity number (RIN) values were Z7. Samples
were reverse transcribed, ampliﬁed and labeled using 30 IVT Express
Kit (Affymetrix). The resultant labeled complementary RNA (cRNA)
was puriﬁed and fragmented as per vendor’s instructions. The cRNA
samples together with probe array controls were hybridized onto
Affymetrix Human Genome U133þ Plus PM array strips, which cover
more than 47,000 transcripts and variants selected from GenBank,
dbEST, and RefSeq. Hybridization controls were spiked into the cRNA
samples to monitor and troubleshoot the hybridization process. Probes
for housekeeping genes were used to assess sample integrity. Hybri-
dization, washing, staining and scanning were performed using
Affymetrix GeneChip system instruments. Affymetrix GeneAtlas
instrument control software version 1.0.5.267 was used to analyze
microarray image data and to compute intensity values. Affymetrix.
CEL ﬁles containing raw, probe-level signal intensities were analyzed
using Partek Genomics Suite version 6.6.12.0713 (Partek). Robust
multichip averaging (RMA) was used for background correction,
quantile normalization and probe set summarization with median
Table 3
TP53 status of PDAC and non-malignant HPDE cell lines.
Cell line Mutant KRAS? Mutant TP53? TP53 sequencing p53 Protein detectionn p53 Dominant negativenn p53 Transactivation classnn
AsPC-1 X X – p.C135fs – – –
T3M4 X X p. P72R p.Y220C þþ Moderate Non-functional
Capan-2 X X – p.R273H þþþ Yes Non-functional
Suit2 X X p. P72R p.R273H þþ Yes Non-functional
HPDE – – p. P72R WT NA – –
Genomic analysis of cell line p53 status by analyzing cellular genomic DNA by two methods: Ion Ampliseq™ Cancer Hotspot Panel for KRAS and TP53 mutations and PCR
with primers VG268 and VG269, which correspond to exons 5 through 9 (where a majority of TP53 mutations occur).
n Western blot was conducted to determine cell line p53 protein expression levels (data not shown).
nn Dominant negative and transactivation status data is from IARC p53 Database (http://p53.iarc.fr/).
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Fig. 9. RT-PCR analysis of selected mRNA transcripts. Suit2, T3M4, Capan-2, and ASPC-1 PDAC cells and HPDE cells were mock treated or infected with VSV-p53wt, VSV-p53-
CC, or VSV-p53-CC/fs, at MOI 5. Total RNA was extracted, reverse transcribed and analyzed by PCR for the indicated genes.
E. Hastie et al. / Virology 483 (2015) 126–140136
polish (195). Statistical difference was calculated by two-way ANOVA
analysis with a false discovery rate (FDR) of 0.05. Pathway analysis was
performed using differentially expressed data 2-fold or higher with
Ingenuity Pathway Analysis software (Ingenuity Systems).
Cell viability assay
Suit2 cells (in triplicate) were seeded in 96-well plates so that
they reached approximately 80% conﬂuence at 24 h. Cells were
mock treated or infected with VSVs at MOI 0.002 or 0.00002. Cell
viability was analyzed at 1, 24, 48, or 96 h p.i. by a 3-(4,5-dimethyl-
2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) cell via-
bility assay (Cat. No. M2128, Sigma-Aldrich).
Western blotting
Cells were seeded in 6-well plates so that they reached
approximately 80% conﬂuence at 24 h, then mock treated or
infected with VSV at MOI 1. At 8, 12, or 18 h p.i., cells were lysed
with cellular lysis buffer (0.0625 M Tris-HCl pH 6.8, 10% glycerol,
2% SDS, 5% 2-mercaptoethanol, 0.02% (w/v) Bromophenol blue).
20 μl of protein lysate was separated by electrophoresis on 10%
SDS PAGE gels and electroblotted to polyvinylidene diﬂuoride
(PVDF) membranes. Membranes were blocked using 5% non-fat
powdered milk in TBS-T [0.5 M NaCl, 20 mM Tris (pH7.5), 0.1%
Tween20]. The following antibodies from Cell Signaling Technol-
ogy were used: p53 (1:2,000; #2524), Phospho-p53 (1:500;
#2521), IRF3 (1:1000, #4302), Phospho-IRF3 (1:1000, #4947),
Stat1 (1:1000, #42H3), and Phospho-Stat1 (1:500, #9171). In
addition, the following primary antibodies were used in TBS-T
with 5% BSA and 1% of 2% sodium azide: 1:5,000 rabbit polyclonal
anti-VSV antibodies (Grdzelishvili et al., 2005). The following
horseradish peroxidase (HRP)-conjugated secondary antibodies
in TBS-T with 5% milk antibodies were used: 1:4,000 goat anti-
mouse and 1:2,000 goat anti-rabbit (catalog no. 115-035-003 and
111-035-003, respectively; Jackson-ImmunoResearch). The Amer-
sham ECL Western Blotting Detection kit (RPN2106; GE Health-
care) or SuperSignal West Pico (34080; Thermo Scientiﬁc) were
used for detection.
RNA RT-PCR analysis
Cells (in duplicate) were seeded in 12-well plates so that they
reached approximately 80% conﬂuence at 24 h. Cells were mock
treated or infected with VSV at MOI 5 based on titration on Suit2
cells. Total RNA was extracted 8 h p.i. with TRIzol as above. 50 μg
of total RNA per reverse transcription (RT) reaction using SMART-
Scribe reverse transcriptase (Clontech) was used for the cDNA
synthesis as per manufacturer’s protocol. PCR was carried out on
cDNA using the following conditions: denaturation at 94 1C for
45 s (s) annealing at 57 1C for 45 s, extension at 72 1C for 45 s for
either 25, 30, or 35 cycles and a ﬁnishing step at 72 1C for 8 min.
All primers for PCR are shown in the Supplementary Table 1 and
were designed to not amplify genomic DNA. PCR products were
electrophoresed on a 2% agarose gel with ethidium bromide and
photographed using a GelDoc-It imager (UVP Imaging). Primers for
RT-PCR are listed in Supplemental Table 1.
Treatment with inhibitors
Suit2 cell were seeded in 12-well plates so that they reached
approximately 80% conﬂuence at 24 h. Cells were mock treated or
infected with VSV at MOI 10. After 1 h, virus-containing media was
removed and cells were either mock treated (0.3 % DMSO) or
treated with 8 μM IKK-2 Inhibitor VIII [purchased from EMD
Millipore (cat. No. 401487)] or 2.5 μM ruxolitinib [purchased from
Selleck Chemicals (cat. No. S1378)] in growth media containing 5%
FBS. Inhibitor treatment also contained 0.3% DMSO. After 8 h
treatment, total RNA was extracted with TRIzol as above. cDNA
was synthesized and PCR was performed as above.
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Fig. 10. Analysis of PDAC and HPDE cell infectivity and cell viability at multiple
MOIs. (A) To determine a relative infectivity of VSV recombinants on different cells
lines (PDAC cells and non-malignant HPDE cells), the same virus stock of each virus
was titrated on different cell lines using plaque assay. The Y-axis shows virus titer
of the same stock for each cell lines, with higher titer indicating higher infectivity of
VSV on the given cell line. (B) and (C) Cells were mock treated or infected with VSV-
p53wt, VSV-p53-CC, or VSV-p53-CC/fs at MOI 0.1 (B) or 10 (C). Cell viability was
analyzed 5 d p.i. by MTT cell viability assay and is expressed as a percentage of
mock-treated cells. All MTT assays were done in triplicate, and the data represent
the means7SEM.
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Cell line genomic mutation proﬁling
Cellular genomic DNA was isolated from PDAC cell lines using
the Life Technologies Purelink Genomic DNA isolation kit. To
analyze cellular DNA for frequent cancer mutations, the Ion
AmpliSeq™ Cancer Hotspot Panel v2 Kit (Life Technologies) con-
taining 207 primer pairs was used to perform multiplex PCR for
the preparation of amplicon libraries from genomic hot spot
regions that are frequently mutated in human genes associated
with cancer, including approximately 2800 Catalogue of Somatic
Mutations in Cancer (COSMIC) mutations of 50 oncogenes and
tumor suppressor genes. Sequencing libraries were prepared using
an Ion AmpliSeq Library Kit (Life Technologies) per manufacturer’s
instructions. Brieﬂy, amplicons were ligated to Ion-compatible
adapters, followed by nick repair to complete the linkage between
adapters and DNA inserts. The libraries were clonally ampliﬁed by
emulsion PCR on Ion Sphere Particles (ISPs) using the Ion One-
Touch 200 Template Kit (Life Technologies) as directed. Following
ampliﬁcation, the template-positive ISPs were enriched to max-
imize the number of sequencing reads produced using the Ion
PGM Sequencing 200 Kit (Life Technologies) on an Ion PGM
Sequencer (Life Technologies) and Ion 314 Chips (Life Technolo-
gies). Raw data was transferred to the Ion PGM Torrent Server for
base calling, preprocessing 30 trimming, quality control and
assessment, and mapping. Variant calling and annotation was
performed using Ion Reporter Software (Life Technologies) and
Ingenuity Variant Analysis Knowledge Module (Ingenuity Systems)
for Ion Reporter. To conﬁrm the identiﬁed p53 mutations, cellular
genomic DNA corresponding to TP53 exons 5 through 9 (where a
majority of TP53 mutations occur) was ampliﬁed by PCR with
primers VG 268 and VG 269 (NM_000546.5, Supplemental
Table 1) prior to sequencing.
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